U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07674121) titled 'PROLONG (PRostateOLaparibONcombinationGcc) Study' on June 09.
Brief Summary: The study will generate regionally relevant data to inform clinical practice, support treatment guidelines, and potentially contribute to supportive evidence for health authority discussions or scientific publications. This aligns with AstraZeneca's strategic goal of expanding the real-world evidence (RWE) base for Olaparib in diverse populations and practice settings. The study also complements the strategic priorities and focus areas, as well as strengthening AstraZeneca's leadership position in the management of prostate cancer and establishing the inten...